| Variant analysis of SARS-CoV-2 genomes T Koyama, D Platt, L Parida Bulletin of the World Health Organization 98 (7), 495, 2020 | 639 | 2020 |
| Emergence of drift variants that may affect COVID-19 vaccine development and antibody treatment T Koyama, D Weeraratne, JL Snowdon, L Parida Pathogens 9 (5), 324, 2020 | 245 | 2020 |
| Enhancing next‐generation sequencing‐guided cancer care through cognitive computing NM Patel, VV Michelini, JM Snell, S Balu, AP Hoyle, JS Parker, ... The oncologist 23 (2), 179-185, 2018 | 111 | 2018 |
| Comparing sequencing assays and human-machine analyses in actionable genomics for glioblastoma KO Wrzeszczynski, MO Frank, T Koyama, K Rhrissorrakrai, N Robine, ... Neurology: Genetics 3 (4), e164, 2017 | 44 | 2017 |
| Watson for genomics: moving personalized medicine forward K Rhrissorrakrai, T Koyama, L Parida Trends in cancer 2 (8), 392-395, 2016 | 20 | 2016 |
| Evaluating clinical genome sequence analysis by Watson for genomics K Itahashi, S Kondo, T Kubo, Y Fujiwara, M Kato, H Ichikawa, T Koyama, ... Frontiers in Medicine 5, 305, 2018 | 19 | 2018 |
| Evasion of vaccine-induced humoral immunity by emerging sub-variants of SARS-CoV-2 T Koyama, K Miyakawa, R Tokumasu, S S Jeremiah, M Kudo, A Ryo Future microbiology 17 (6), 417-424, 2022 | 17 | 2022 |
| Introductions and evolutions of SARS-CoV-2 strains in Japan R Tokumasu, D Weeraratne, J Snowdon, L Parida, M Kudo, T Koyama medRxiv, 2021.02. 26.21252555, 2021 | 12 | 2021 |
| Emergence of drift variants that may affect COVID-19 vaccine development and antibody treatment. Pathogens. 2020; 9 (5): 324 T Koyama, D Weeraratne, JL Snowdon, L Parida | 11 | |
| Sequencing and curation strategies for identifying candidate glioblastoma treatments MO Frank, T Koyama, K Rhrissorrakrai, N Robine, F Utro, AK Emde, ... BMC medical genomics 12, 1-16, 2019 | 10 | 2019 |
| Analysis on GENIE reveals novel recurrent variants that affect molecular diagnosis of sizable number of cancer patients T Koyama, K Rhrissorrakrai, L Parida BMC cancer 19, 1-12, 2019 | 7 | 2019 |
| Cross-border transmissions of the Delta substrain AY. 29 during Tokyo Olympic and Paralympic games T Koyama, R Tokumasu, K Katayama, A Saito, M Kudo, S Imoto Frontiers in microbiology 13, 883849, 2022 | 6 | 2022 |
| Single kick approximations for beam-beam deflections T Koyama Physical Review Special Topics-Accelerators and Beams 2 (2), 024001, 1999 | 6 | 1999 |
| Identification of a low pathogenicity clade of SARS-CoV-2 T Koyama, L Parida | 5 | 2020 |
| Molecular and epidemiological characterization of emerging immune-escape variants of SARS-CoV-2 K Miyakawa, SS Jeremiah, Y Yamaoka, T Koyama, R Tokumasu, M Kudo, ... Frontiers in Medicine 9, 811004, 2022 | 4 | 2022 |
| Intelligent personalized chemical synthesis planning A Kishimoto, AI Botea, B Buesser, B Chen, T Koyama US Patent 11,735,292, 2023 | 3 | 2023 |
| Simplified visualization and relevancy assessment of biological pathways B Carmeli, B Erhan, T Koyama, K Rhrissorrakrai, A Royyuru, U Filippo, ... US Patent 10,546,019, 2020 | 3 | 2020 |
| Quantitative assessment of drug recommendations T Koyama, K Rhrissorrakrai, U Filippo US Patent App. 14/968,140, 2017 | 2 | 2017 |
| Reviews of" Emergence of a novel SARS-CoV-2 strain in Southern California, USA" T Koyama, F Balloux, LW Riley Rapid Reviews Infectious Diseases, 2021 | 1 | 2021 |
| Abstract P3-09-07: A multicenter phase Ib/II study for evaluating safety and efficacy of Nivolumab in combination with radiation therapy in patients with HER2-negative … M Takada, M Yoshimura, K Kawaguchi, T Kotake, R Uozumi, M Kataoka, ... Cancer Research 80 (4_Supplement), P3-09-07-P3-09-07, 2020 | 1 | 2020 |
